REVB Revelation Biosciences, Inc. - Common Stock
$1.16
Price · Aug 19, 2026
Fundamentals as of May 7, 2026
52W Range
$0–$3
28% of range
Analyst Rating
BUY
7 analysts
Price Target
$19
+1559% upside
P/E (TTM)
—
ROE
—
Net Profit Margin
—
REVB Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$1.16
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$0 – $3
REVB Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
REVB
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
REVB
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
REVB
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
REVB
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
REVB
Peer Median
REVB Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
7 analysts
- Strong Buy 2 28.6%
- Buy 4 57.1%
- Hold 1 14.3%
- Sell 0 0.0%
- Strong Sell 0 0.0%
12-Month Price Target
2 analysts · 2026-08-15
Median
$19.25
← Below all targets
$1.16
Low
$16.00
High
$22.50
Median target
$19.25
+1559.5%
Mean target
$19.25
+1559.5%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
4.3%
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| June 30, 2026 | $-0.87 | $-0.85 | -0.02% |
| March 31, 2026 | $-2.71 | $-1.17 | -1.5% |
| Dec. 31, 2025 | $-23.95 | $-3.73 | -20.2% |
| Sept. 30, 2025 | $-7.08 | $-5.45 | -1.6% |
| June 30, 2025 | $-28.04 | $-18.18 | -9.9% |
| March 31, 2025 | $-25.32 | $-84.21 | 58.9% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| REVB | — | — | — | — | — | — |
| APVO | $9M | -0.1 | — | — | -217.2% | — |
| MBRX | — | — | — | — | — | — |
| HCWB | — | -0.1 | -97.9% | -14677.1% | -586.8% | 20.0% |
| SILO | $5M | -0.7 | 0.00% | -5863.5% | -75.3% | 38.6% |
| VIVS | $4M | -0.3 | -9.0% | -10567.2% | -294.8% | — |
| CRIS | $13M | -1.7 | -13.4% | -80.3% | 177.9% | — |
| RNAZ | — | -0.1 | — | — | — | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 12
| Metric | Trend | Q1 2026 | Q2 2024 |
|---|---|---|---|
| R&D Expense | $1M | $1M | |
| SG&A Expense | $2M | $1M | |
| Operating Expenses | $3M | $3M | |
| Operating Income | $-3M | $-3M | |
| Other Non-op | $83.4K | $-6M | |
| Income Tax | · | $0 | |
| Net Income | $-3M | $-8M | |
| EPS (Basic) | $-2.71 | $-5.13 | |
| EPS (Diluted) | $-2.71 | $-5.13 | |
| Shares (Basic) | 3,207,720 | 1,635,234 | |
| Shares (Diluted) | 3,207,720 | 1,635,234 | |
| EBITDA | $-3M | $-3M |
Balance Sheet 19
| Metric | Trend | Q1 2026 | Q2 2024 |
|---|---|---|---|
| Cash & Equivalents | $14M | $12M | |
| Prepaid Expense | $92.6K | $125.7K | |
| Current Assets | $14M | $12M | |
| PP&E (Net) | $140.7K | $70.8K | |
| PP&E (Gross) | $246.9K | $151.1K | |
| Accum. Depreciation | $106.2K | $80.4K | |
| Other Non-current Assets | $30.9K | · | |
| Total Assets | $15M | $12M | |
| Accounts Payable | $828.2K | $1M | |
| Accrued Liabilities | $468.1K | $8M | |
| Current Liabilities | $1M | $11M | |
| Capital Leases | $638.2K | · | |
| Total Liabilities | $2M | $11M | |
| Common Stock | $3.9K | $1.6K | |
| Paid-in Capital | $65M | $38M | |
| Retained Earnings | $-52M | $-37M | |
| Stockholders' Equity | $13M | $1M | |
| Liabilities + Equity | $15M | $12M | |
| Shares Outstanding | 3,908,420 | 1,643,395 |
Cash Flow 6
| Metric | Trend | Q1 2026 | Q2 2024 |
|---|---|---|---|
| Stock-based Comp | $471.0K | · | |
| Operating Cash Flow | $-3M | · | |
| CapEx | $71.9K | · | |
| Investing Cash Flow | $-71.9K | · | |
| Financing Cash Flow | $7M | · | |
| Free Cash Flow | $-3M | · |
Profitability 2
| Metric | Trend | Q1 2026 | Q2 2024 |
|---|---|---|---|
| ROA | -31.6% | -59.3% | |
| ROE | -37.9% | -133.7% |
Liquidity & Solvency 2
| Metric | Trend | Q1 2026 | Q2 2024 |
|---|---|---|---|
| Current Ratio | 10.0 | 1.1 | |
| Quick Ratio | 10.0 | 1.1 |
Valuation (TTM) 8
| Metric | Trend | Q1 2026 | Q2 2024 |
|---|---|---|---|
| Net Income TTM | $-9M | $-15M | |
| Market Cap | $5M | $151M | |
| P/E | -0.0 | -0.3 | |
| P/B | 0.4 | 132.1 | |
| P / Tangible Book | 0.4 | 132.1 | |
| P / Cash Flow | -1.5 | · | |
| P / FCF | -1.4 | · | |
| Earnings Yield | -3069.2% | -328.8% |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 13 filers · $338K total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 4 | 3 | 2 | 1 | — |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair. Change vs prior quarter not shown: filer coverage differs too much between these two quarters for a reliable comparison.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| SABBY MANAGEMENT, LLC | $216,899 | 210,582 | 64.24% | Shares |
| VANGUARD GROUP INC | $42,004 | 52,505 | 12.44% | Shares |
| CITADEL ADVISORS LLC | $39,736 | 38,579 | 11.77% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $17,142 | 16,643 | 5.08% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $13,521 | 13,127 | 4.00% | Shares |
| Tower Research Capital LLC (TRC) | $6,724 | 6,528 | 1.99% | Shares |
| ROYAL BANK OF CANADA | $1,000 | 747 | 0.30% | Shares |
| SBI Securities Co., Ltd. | $354 | 344 | 0.10% | Shares |
| BARCLAYS PLC | $173 | 168 | 0.05% | Shares |
| HARBOUR INVESTMENTS, INC. | $42 | 41 | 0.01% | Shares |
| HRT FINANCIAL LP | $17 | 16,978 | 0.01% | Shares |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $9 | 9 | 0.00% | Shares |
| Caitong International Asset Management Co., Ltd | $1 | 1 | 0.00% | Shares |
Company insiders 9 insiders · 4 officers · 8 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| James Rolke | Chief Executive Officer | April 30, 2026 F | 214,738 | 0 | 0 | $0 |
| Sean H Fitzpatrick | Chief Executive Officer | Dec. 30, 2020 J | 1,769,538 | 0 | 0 | $0 |
| Andreas Typaldos | Chief Executive Officer | Dec. 30, 2020 J | 1,769,538 | 0 | 0 | $0 |
| Chester Stanley Zygmont III | Chief Financial Officer | April 30, 2026 F | 92,063 | 0 | 0 | $0 |
| Jennifer Carver | Director | Feb. 3, 2026 F | 12,758 | 0 | 0 | $0 |
| Lakhmir S Chawla | Director | Feb. 3, 2026 F | 12,158 | 0 | 0 | $0 |
| Jess Roper | Director | Feb. 3, 2026 F | 12,828 | 0 | 0 | $0 |
| George F Tidmarsh | Director | Feb. 11, 2025 A | 268 | 0 | 0 | $0 |
| Curt H Labelle | Director | April 14, 2023 A | — | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only